Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
University of California, San Francisco
AstraZeneca
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Gan & Lee Pharmaceuticals.
University of Wisconsin, Madison
Alterome Therapeutics, Inc.
Amgen
Merck Sharp & Dohme LLC
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
University of Chicago
ViroMissile, Inc.
Dana-Farber Cancer Institute
Vir Biotechnology, Inc.
University of Texas Southwestern Medical Center
University of Pennsylvania
National Institutes of Health Clinical Center (CC)
C Ray Therapeutics
Roswell Park Cancer Institute
SURGE Therapeutics
Tizona Therapeutics, Inc
Genentech, Inc.
Astellas Pharma Inc
Leiden University Medical Center
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Clasp Therapeutics, Inc.
Eli Lilly and Company
Angiex, Inc.
IDEAYA Biosciences
AdventHealth
Astellas Pharma Inc
Bristol-Myers Squibb
ARTBIO Inc.
Novartis
City of Hope Medical Center
Amgen